Inhibikase Therapeutics
IKT----
Inhibikase Therapeutics (IKT)
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, w...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Inhibikase Therapeutics Analyst Rating
View MoreForecast & Rating
Jul 13, 2026Price forecast
$6.00157.51%
Forecast & RatingStrong buy
9analysts
- Strong buy88.89%
- Buy11.11%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · 1 day ago, 07:07 AM
Inhibikase wins FDA orphan drug designation for IKT-001 in PAH
- PUBT · Jul 17 at 04:55 PM
RA Capital Management files initial beneficial ownership statement in Inhibikase Therapeutics
- Tip Ranks · Jul 15 at 03:05 AM
Inhibikase raises $50M to fund PAH program
- rttnews · Jul 15 at 02:55 AM
Biotech Stocks Hit 52-Week Highs - TOI, IKT, ANRO, ELV, PRVA
- PUBT · Jul 14 at 07:01 AM
Inhibikase Therapeutics sells 25,000,000 shares via ATM for gross proceeds of $50 million
- PUBT · Jul 2 at 03:01 PM
Inhibikase grants stock options for 981,243 shares to seven new hires under inducement plan at $2.03 per share
